GSK Plans Further Divestments As Pfizer Brands Drive Up Q3 Sales
Executive Summary
GSK is plotting further divestments into next year as it looks to focus its portfolio on key categories and raise funds to cover the costs of integrating Pfizer's Consumer Healthcare business. In the third quarter, GSK's sales advanced double-digits thanks to the inclusion of Pfizer megabrands like Advil and Centrum.
You may also be interested in...
GSK Promises 'Greater Transparency' From Consumer Brand Reshuffle
In the wake of its joint venture with Pfizer, GSK Consumer Healthcare has shaken up how it reports its sales by category to highlight the "main drivers" of performance.
Stada Grabs GSK Brands In EU
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.
Stada Grabs GSK Brands In Key EU Markets
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.